Given chromatin’s activity and continuous adaptations, the therapeutic use of HDAC inhibitors to treat mood disorders is promising, though the half-life and affinity of any HDAC inhibitor may also define its potential risk for toxicity and undesirable side effects in vivo (Machado-Vieira et al., 2011a). The gene discussed is HDAC9; the disease is mood disorder.